mean to say valuation is around 250 (leaving cash) after q1 burn. The drug could net $300m/year in the US alone. I don't get valuation is so low. Why wouldn't a big pharma acquirer make an offer at a premium say 40%
Why not Bayer? They certainly would have the contacts and incentive to make it happen. It does make me a little suspicious why this not only didn't go up on the good news but went down. Possible but unlikely.